JAK2 and myeloid neoplasm: Among the selected myeloid tumor cell lines, the HEL cell line is a human erythroleukemia cell line with JAK2V617F mutation, which as shown in Figure 1(g), when the ITGB3 expression was compared to all other cell lines harboring wild type JAK2, it was markedly higher.